TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Teva shares closed at $43.24, up 1.24% on volume of nearly 7 million shares, as the company hosted its first-ever R&D Day and unveiled an aggressive long-range growth plan. Management set a goal of $6 billion to $7 billion in sales from newly developed treatments by 2030, with the higher-end $7 billion figure cited as the target from novel drugs. The bullish product-focused news, rated high impact, likely supported the stock's gain on the day. The direction signal from today's catalysts is positive.

Teva reported third-quarter 2026 adjusted EPS of $0.86 on revenue of $4.395 billion, both topping analyst forecasts, and raised its full-year 2026 adjusted EPS guidance to $1.92-$2.11 and sales outlook to $16.7B-$17.0B. The stock closed essentially flat at $41.91 (+0.01%) despite trading as high as $43.34 intraday, suggesting the strong results and guidance raise were largely priced in or offset by profit-taking. Management also highlighted robust Austedo demand expected to cushion a 2027 Medicare pricing hit, while noting the newly launched Weltruza won't contribute meaningful revenue until H2 2027. Separately, Teva signed a U.S. commercialization deal with Samsung Bioepis for two approved biosimilars, reinforcing its generics and biosimilars growth strategy. Overall, the news flow skews bullish on earnings and pipeline execution, though the muted price reaction signals a neutral-to-modestly-positive near-term direction.